| Autor: |
Xiong, Chengjie, Luo, Jingqin, Wolk, David A., Shaw, Leslie M., Roberson, Erik D., Murchison, Charles F., Henson, Rachel L., Benzinger, Tammie L. S., Bui, Quoc, Agboola, Folasade, Grant, Elizabeth, Gremminger, Emily N., Moulder, Krista L., Geldmacher, David S., Clay, Olivio J., Babulal, Ganesh, Cruchaga, Carlos, Holtzman, David M., Bateman, Randall J., Morris, John C. |
| Předmět: |
|
| Zdroj: |
Nature Communications; 7/2/2024, Vol. 15 Issue 1, p1-10, 10p |
| Abstrakt: |
Blood-based biomarkers of Alzheimer disease (AD) may facilitate testing of historically under-represented groups. The Study of Race to Understand Alzheimer Biomarkers (SORTOUT-AB) is a multi-center longitudinal study to compare AD biomarkers in participants who identify their race as either Black or white. Plasma samples from 324 Black and 1,547 white participants underwent analysis with C2N Diagnostics' PrecivityAD test for Aβ42 and Aβ40. Compared to white individuals, Black individuals had higher average plasma Aβ42/40 levels at baseline, consistent with a lower average level of amyloid pathology. Interestingly, this difference resulted from lower average levels of plasma Aβ40 in Black participants. Despite the differences, Black and white individuals had similar longitudinal rates of change in Aβ42/40, consistent with a similar rate of amyloid accumulation. Our results agree with multiple recent studies demonstrating a lower prevalence of amyloid pathology in Black individuals, and additionally suggest that amyloid accumulates consistently across both groups. Plasma samples from 324 Black and 1,547 white participants underwent analysis with C2N Diagnostics' Precivity AD test for Aβ42 and Aβ40. Compared to white individuals, Black individuals had higher average plasma Aβ42/40 levels at baseline, consistent with a lower average level of amyloid pathology. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink